Characterization of Non-Specific Uptake and Retention Mechanisms of [¹⁷⁷Lu]Lu-PSMA-617 in the Salivary Glands

• Váldodahkkit: Nathalie Heynickx (Dahkki), Charlotte Segers (Dahkki), Amelie Coolkens (Dahkki), Sarah Baatout (Dahkki), Koen Vermeulen (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2023-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The radionuclide therapy [¹⁷⁷Lu]Lu-PSMA-617 was recently FDA-approved for treatment of metastatic castration-resistant prostate cancer. Salivary gland toxicity is currently considered as the main dose-limiting side effect. However, its uptake and retention mechanisms in the sa...